Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GoPro Inc (GPRO) vs McKesson Corporation (MCK) Price & Performance

McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

GoPro Inc vs McKesson Corporation — how do they compare? GoPro Inc trades at $1.19 (market cap $253.82M), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 418.2× GoPro Inc's market cap, and McKesson Corporation pays a 0.41% dividend while GoPro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and McKesson Corporation for 74 Days on average.

GPROMCK
Market Cap
$253.82M$106.14B
Volume
9,909,466794,405
Sector
TechnologyHealth
52-Week High
$2.35$995.69
52-Week Low
$0.58$725.17
Typical Hold Time
45 Days74 Days
Enterprise Value
$312.60M$112.67B
Dividend Yield
—0.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GoPro Inc

GoPro (GPRO) trades at $1.18, down 10.61% today amid volatile trading following recent merger announcements. The stock shows bullish technical signals with oversold RSI conditions, while fundamentally the company faces significant challenges with negative profit margins and declining revenue. Recent developments include a proposed $285 million merger with Starman Optical and influencer Markiplier taking an 8.5% stake, driving substantial price volatility.

Investment outlook remains highly speculative with the merger offering potential upside from the $1.14 buyout price, but fundamental weakness and negative cash flow pose substantial risks. Analyst sentiment is mixed with only 21% recommending buy, while ongoing investigations into the merger's fairness add uncertainty to the transaction's completion.

McKesson Corporation

McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.

Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GPRO
92% Buy8% Sell
Avg holding period · 45 Days
MCK
40% Buy60% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About GoPro Inc

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.

Read more on GPRO →

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →